Christoph Erkel & VERAXA Biotech AG

Christoph Erkel: Erkel was promoted from VP of R&D to CSO, bringing 20 years of antibody therapeutics experience to lead VERAXA's pipeline.

VERAXA Biotech AG: VERAXA appointed a new CSO to lead its BiTAC platform development, indicating continuity in its strategic direction.

Christoph Erkel: Christoph Erkel, Vice President Research & Development at VERAXA Biotech AG, confirmed the working concept of the BiTAC-ADC platform for selectively delivering toxic payloads to tumor cells.

VERAXA Biotech AG: VERAXA Biotech AG announced positive in vitro proof-of-concept data for its BiTAC-ADC technology platform, which could lead to more precise cancer therapies and enhance its market position. The company is seeking partnering opportunities based on this technology.

Christoph Erkel: As CSO of VERAXA, he commented on the achievement, highlighting the partnership's success.

VERAXA Biotech AG: VERAXA is the lead developer of VXA-222; the milestone advances its pipeline and strengthens its position in bispecific ADCs.

Christoph Erkel: Christoph Erkel, VP Research & Development of VERAXA Biotech AG, commented on the importance of the collaboration with Atum for accelerating the BiTAC-TCE program.

VERAXA Biotech AG: VERAXA Biotech AG initiated cell line development for its lead BiTAC-TCE program with Atum, a crucial step towards clinical development and potential market entry for its cancer therapies.

Christoph Erkel: Christoph Erkel, VP of R&D at VERAXA, commented on the regulatory feedback, highlighting its importance for efficient clinical progression.

VERAXA Biotech AG: VERAXA received supportive regulatory feedback for its lead BiTAC-TCE program, de-risking development and potentially enhancing its pipeline value.